News on LARS from BioPortfolio.com http://www.BioPortfolio.com Consolidated LARS news from BioPortfolio.com Wed, 10 Feb 2010 05:37:31 GMT en Artimplant: Year-End Report 2009 is Published on February 11 2010 at Approximately 8:45 Am (CET) with Conferenhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031166&HITNO=0&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031166&THISHREF=http://c.moreover.com/click/here.pl%3fz2534039564%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031166&HITNO=0&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031166&THISHREF=http://c.moreover.com/click/here.pl%3fz2534039564%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: Research and Markets: Incredible Anaerobes: From Physiology to Genomics to Fuelshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028142&HITNO=1&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028142&THISHREF=http://c.moreover.com/click/here.pl%3fz2532595416%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028142&HITNO=1&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028142&THISHREF=http://c.moreover.com/click/here.pl%3fz2532595416%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Conditionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025430&HITNO=2&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025430&THISHREF=http://c.moreover.com/click/here.pl%3fz2529766191%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025430&HITNO=2&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025430&THISHREF=http://c.moreover.com/click/here.pl%3fz2529766191%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Cellectricon Files Patent Infringement Suit Against Fluxion Bioscienceshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025058&HITNO=3&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025058&THISHREF=http://c.moreover.com/click/here.pl%3fz2529395948%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025058&HITNO=3&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025058&THISHREF=http://c.moreover.com/click/here.pl%3fz2529395948%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Focal Cartilage Defects in the Knee Impair Quality of Life as Much as Severe Osteoarthritis: A Comparison of Khttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024628&HITNO=4&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024628&THISHREF=http://c.moreover.com/click/here.pl%3fz2529009656%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024628&HITNO=4&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024628&THISHREF=http://c.moreover.com/click/here.pl%3fz2529009656%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAmerican Journal of Sports Medicine: An In Vitro Analysis of an Anatomical Medial Knee Reconstructionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024612&HITNO=5&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024612&THISHREF=http://c.moreover.com/click/here.pl%3fz2529008063%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024612&HITNO=5&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024612&THISHREF=http://c.moreover.com/click/here.pl%3fz2529008063%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAmerican Journal of Sports Medicine: Pharmadule targets China with Morimatsu accordhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014531&HITNO=6&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014531&THISHREF=http://c.moreover.com/click/here.pl%3fz2524044939%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014531&HITNO=6&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014531&THISHREF=http://c.moreover.com/click/here.pl%3fz2524044939%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIn-Pharmatechnologist: Novo Nordisk Q4 net profit decreases - Zibb.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014371&HITNO=7&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014371&THISHREF=http://c.moreover.com/click/here.pl%3fz2523982068%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014371&HITNO=7&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014371&THISHREF=http://c.moreover.com/click/here.pl%3fz2523982068%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: Novo Nordisk Q4 net profit decreaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014212&HITNO=8&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014212&THISHREF=http://c.moreover.com/click/here.pl%3fz2523930815%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014212&HITNO=8&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014212&THISHREF=http://c.moreover.com/click/here.pl%3fz2523930815%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comQuote.com Japan: Novo Nordisk Q4 net profit decreaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014093&HITNO=9&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014093&THISHREF=http://c.moreover.com/click/here.pl%3fz2523890552%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014093&HITNO=9&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014093&THISHREF=http://c.moreover.com/click/here.pl%3fz2523890552%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: BP's new chairman buys bighttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006575&HITNO=10&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006575&THISHREF=http://c.moreover.com/click/here.pl%3fz2520783401%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006575&HITNO=10&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006575&THISHREF=http://c.moreover.com/click/here.pl%3fz2520783401%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMoney Week: Pharmadule AB: Pharmadule Strengthens Its Presence in the Chinese Markethttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003641&HITNO=11&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003641&THISHREF=http://c.moreover.com/click/here.pl%3fz2519624993%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003641&HITNO=11&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003641&THISHREF=http://c.moreover.com/click/here.pl%3fz2519624993%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire: Victoza Gains FDA Approvalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007286&HITNO=12&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007286&THISHREF=http://c.moreover.com/click/here.pl%3fz2521068528%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007286&HITNO=12&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007286&THISHREF=http://c.moreover.com/click/here.pl%3fz2521068528%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDrug Discovery and Development: Drug maker's growth offset by costshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004271&HITNO=13&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004271&THISHREF=http://c.moreover.com/click/here.pl%3fz2519875102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004271&HITNO=13&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004271&THISHREF=http://c.moreover.com/click/here.pl%3fz2519875102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Europe: Novo Nordisk receives US approval for Victoza (liraglutide)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004268&HITNO=14&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004268&THISHREF=http://c.moreover.com/click/here.pl%3fz2519874073%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004268&HITNO=14&MSIZE=342&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=LARS&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004268&THISHREF=http://c.moreover.com/click/here.pl%3fz2519874073%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Europe: